Jim Wassil - 09 Mar 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
CHIEF OPERATING OFFICER
Signature
Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
09 Mar 2026
Net transactions value
-$435,440
Form type
4
Filing time
11 Mar 2026, 17:23:16 UTC
Previous filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wassil Jim CHIEF OPERATING OFFICER C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact 11 Mar 2026 0001813798

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Tax liability -975 -0.56% $59.32* 174,213 09 Mar 2026 Direct F1
transaction PCVX Common Stock Sale $141,533 -2,427 -1.4% $58.32 171,786 10 Mar 2026 Direct F2, F3
transaction PCVX Common Stock Sale $293,907 -4,968 -2.9% $59.16 166,818 10 Mar 2026 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $57.725 to $58.715. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.